{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:46:13Z","timestamp":1790196373903,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08 AI135072"],"award-info":[{"award-number":["K08 AI135072"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["GM13172"],"award-info":[{"award-number":["GM13172"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI156807-01"],"award-info":[{"award-number":["AI156807-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI156807-01"],"award-info":[{"award-number":["AI156807-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["CAMS 1017213"],"award-info":[{"award-number":["CAMS 1017213"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>For much of the last decade, tuberculosis (TB) was the leading cause of mortality due to an infectious pathogen (<jats:italic>Mycobacterium tuberculosis<\/jats:italic>, M.tb). Approximately 1.3\u00a0million deaths in 2023 worldwide were attributed to TB disease. Focused intervention strategies to block transmission would significantly reduce the global health burden of TB. Mycobacteriophages (phages) are a sorely underutilized biologic therapy for the pathogen M.tb, and here we aimed to address outstanding questions about their utility for clinical applications. We aimed to determine the impact of repeated mucosal or intravenous (IV) delivery of representative anti-M.tb phage Fionnbharth\u039445\u039447 (Fionnbharth) in a preclinical mouse model. In addition, we specifically sought to understand which route induced anti-phage antibodies, which may reduce the long-term impact of phage therapy. C57BL\/6 mice were dosed weekly for 6 weeks by either route and serum and bronchoalveolar lavage fluid (BALf) were evaluated for anti-phage humoral responses by ELISA. We found that aerosol delivery disperses phage across all lung lobes where M.tb is also found after experimental infection by the same route. Repeated aerosol delivery was well tolerated and did not induce robust neutralizing humoral immunity. In contrast, Mice receiving IV phage developed increasing magnitude and neutralizing total IgG and IgA responses over time. To determine whether pre-treatment environmental exposure to Fionnbharth-like phages could induce antibody responses that are potentially neutralizing, ~\u2009500 human plasma samples from normal donors were evaluated by ELISA. We observed that 5% of samples had antibodies to Fionnbharth (with end point titers\u2009&gt;\u200910<jats:sup>\u2212\u20093<\/jats:sup> dilution), although none were neutralizing. Furthermore, we found that highly-purified phage preparations did not activate mouse or human derived toll like receptor (TLR) 4 or TLR9 in HEKblue reporter assays. These data together support using Fionnbharth in anti-M.tb therapy phage cocktail strategies and that aerosol delivery should be prioritized for further efficacy testing.<\/jats:p>","DOI":"10.1186\/s12985-024-02552-2","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:25:14Z","timestamp":1737379514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery"],"prefix":"10.1186","volume":"22","author":[{"given":"Thomas","family":"Smytheman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pecor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Ferede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhavi","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Harband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem F. M.","family":"Abdelaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Guerrero-Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista G.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney E.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham F.","family":"Hatfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2552_CR1","unstructured":"World Heath Organization. Global Tuberculosis Report (2023)."},{"key":"2552_CR2","unstructured":"World Health Organization. Global tuberculosis report (2019)."},{"key":"2552_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1473-3099(15)00499-5","volume":"16","author":"TA Yates","year":"2016","unstructured":"Yates TA, et al. The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infect Dis. 2016;16:227\u201338.","journal-title":"Lancet Infect Dis"},{"key":"2552_CR4","doi-asserted-by":"publisher","first-page":"g4643","DOI":"10.1136\/bmj.g4643","volume":"349","author":"A Roy","year":"2014","unstructured":"Roy A, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349:g4643.","journal-title":"BMJ"},{"key":"2552_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470\u201380.","journal-title":"Clin Infect Dis"},{"key":"2552_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","volume":"17","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis. Health Technol Assess. 2013;17:1\u2013v372.","journal-title":"Health Technol Assess"},{"key":"2552_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.tube.2011.12.003","volume":"92","author":"H McShane","year":"2012","unstructured":"McShane H, et al. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinb). 2012;92:283\u20138.","journal-title":"Tuberculosis (Edinb)"},{"key":"2552_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1183\/09031936.00086514","volume":"44","author":"C Herzmann","year":"2014","unstructured":"Herzmann C, et al. Early BCG vaccination is unrelated to pulmonary immunity against Mycobacterium tuberculosis in adults. Eur Respir J. 2014;44:1087\u201390.","journal-title":"Eur Respir J"},{"key":"2552_CR9","doi-asserted-by":"publisher","first-page":"eaax4607","DOI":"10.1126\/scitranslmed.aax4607","volume":"12","author":"RC Harris","year":"2020","unstructured":"Harris RC, Sumner T, Knight GM, Zhang H, White RG. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med. 2020;12:eaax4607.","journal-title":"Sci Transl Med"},{"key":"2552_CR10","doi-asserted-by":"crossref","unstructured":"Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett. 2016;363.","DOI":"10.1093\/femsle\/fnv242"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick RM, et al. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis. 2023;76:103\u201312.","journal-title":"Clin Infect Dis"},{"key":"2552_CR12","doi-asserted-by":"crossref","unstructured":"Carrigy NB et al. Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrob Agents Chemother. 2019;63(12):e00871\u20139","DOI":"10.1128\/AAC.00871-19"},{"key":"2552_CR13","doi-asserted-by":"crossref","unstructured":"Guerrero-Bustamante CA, Dedrick RM, Garlena RA, Russell DA, Hatfull GF. Toward a Phage Cocktail for Tuberculosis: Susceptibility and Tuberculocidal Action of Mycobacteriophages against Diverse Mycobacterium tuberculosis Strains. mBio. 2021;12.","DOI":"10.1128\/mBio.00973-21"},{"key":"2552_CR14","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1038\/s41467-022-29689-4","volume":"13","author":"JS Little","year":"2022","unstructured":"Little JS, et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat Commun. 2022;13:2313.","journal-title":"Nat Commun"},{"key":"2552_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med. 2021;27:1357\u201361.","journal-title":"Nat Med"},{"key":"2552_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730\u20133.","journal-title":"Nat Med"},{"key":"2552_CR17","first-page":"145","volume":"101","author":"GJ Sarkis","year":"1998","unstructured":"Sarkis GJ, Hatfull GF. Mycobacteriophages Methods Mol Biol. 1998;101:145\u201373.","journal-title":"Mycobacteriophages Methods Mol Biol"},{"key":"2552_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-60327-164-6_7","volume":"501","author":"AM Kropinski","year":"2009","unstructured":"Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol. 2009;501:69\u201376.","journal-title":"Methods Mol Biol"},{"key":"2552_CR19","doi-asserted-by":"publisher","first-page":"e0274078","DOI":"10.1371\/journal.pone.0274078","volume":"17","author":"WE Harrington","year":"2022","unstructured":"Harrington WE, et al. Low rate of SARS-CoV-2 incident infection identified by weekly screening PCR in a prospective year-long cohort study. PLoS ONE. 2022;17:e0274078.","journal-title":"PLoS ONE"},{"key":"2552_CR20","doi-asserted-by":"crossref","unstructured":"Carroll-Portillo A, Lin HC. Bacteriophage and the Innate Immune System: Access and Signaling. Microorganisms. 2019;7.","DOI":"10.3390\/microorganisms7120625"},{"key":"2552_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.chom.2019.01.008","volume":"25","author":"L Gogokhia","year":"2019","unstructured":"Gogokhia L, et al. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe. 2019;25:285\u2013e299288.","journal-title":"Cell Host Microbe"},{"key":"2552_CR22","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1038\/s41598-021-86112-6","volume":"11","author":"KS Wetzel","year":"2021","unstructured":"Wetzel KS, et al. CRISPY-BRED and CRISPY-BRIP: efficient bacteriophage engineering. Sci Rep. 2021;11:6796.","journal-title":"Sci Rep"},{"key":"2552_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3389\/fmicb.2019.00954","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. Genetic Engineering of Bacteriophages Against Infectious Diseases. Front Microbiol. 2019;10:954.","journal-title":"Front Microbiol"},{"key":"2552_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.tibtech.2022.08.008","volume":"41","author":"M Mahler","year":"2023","unstructured":"Mahler M, Costa AR, van Beljouw SPB, Fineran PC, Brouns SJJ. Approaches for bacteriophage genome engineering. Trends Biotechnol. 2023;41:669\u201385.","journal-title":"Trends Biotechnol"},{"key":"2552_CR25","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick JA, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022;185:1860\u2013e18741812.","journal-title":"Cell"},{"key":"2552_CR26","doi-asserted-by":"crossref","unstructured":"Kang D, Bagchi D, Chen IA. Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy. Weinh. 2024;7.","DOI":"10.1002\/adtp.202300355"},{"key":"2552_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/jamp.2015.1233","volume":"29","author":"KY Liu","year":"2016","unstructured":"Liu KY, et al. Inhalation Study of Mycobacteriophage D29 Aerosol for Mice by Endotracheal Route and Nose-Only Exposure. J Aerosol Med Pulm Drug Deliv. 2016;29:393\u2013405.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2552_CR28","doi-asserted-by":"publisher","first-page":"ofac194","DOI":"10.1093\/ofid\/ofac194","volume":"9","author":"RM Dedrick","year":"2022","unstructured":"Dedrick RM, et al. Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease. Open Forum Infect Dis. 2022;9:ofac194.","journal-title":"Open Forum Infect Dis"},{"key":"2552_CR29","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.tim.2023.04.008","volume":"31","author":"K Champagne-Jorgensen","year":"2023","unstructured":"Champagne-Jorgensen K, Luong T, Darby T, Roach DR. Immunogenicity of bacteriophages. Trends Microbiol. 2023;31:1058\u201371.","journal-title":"Trends Microbiol"},{"key":"2552_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bioinformatics\/btw711","volume":"33","author":"DA Russell","year":"2017","unstructured":"Russell DA, Hatfull GF. PhagesDB: the actinobacteriophage database. Bioinformatics. 2017;33:784\u20136.","journal-title":"Bioinformatics"},{"key":"2552_CR31","doi-asserted-by":"publisher","first-page":"e06416","DOI":"10.7554\/eLife.06416","volume":"4","author":"WH Pope","year":"2015","unstructured":"Pope WH, et al. Whole genome comparison of a large collection of mycobacteriophages reveals a continuum of phage genetic diversity. Elife. 2015;4:e06416.","journal-title":"Elife"},{"key":"2552_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.pmbts.2023.03.016","volume":"201","author":"CJ Opperman","year":"2023","unstructured":"Opperman CJ, Wojno J, Goosen W, Warren R. Phages for the treatment of Mycobacterium species. Prog Mol Biol Transl Sci. 2023;201:41\u201392.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2552_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1186\/s12879-022-07944-9","volume":"22","author":"F Zeynali Kelishomi","year":"2022","unstructured":"Zeynali Kelishomi F, et al. Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review. BMC Infect Dis. 2022;22:957.","journal-title":"BMC Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02552-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:25:19Z","timestamp":1737379519000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02552-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02552-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}